Internal Med Medical News about Lovastatin

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

4. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

5. Rapid correction of low vitamin D status in nursing home residents

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Safety of Lovastatin/Extended Release Niacin Compared With Lovastatin Alone, Atorvastatin Alone, Pravastatin Alone, and Simvastatin Alone
The American Journal of Cardiology, 03/05/07

Alsheikh-Ali, Alawi A. MD., et al. – Are the label warnings about increased risk of adverse events with statin and niacin combinations valid?
>Summary: A comparison review of the rate of adverse event reports (AERs) received by the United States Food and Drug Administration from 1999 to March 2005 associated with the combination of lovastatin/niacin-extended release (ER) with those of lovastatin or niacin-ER alone, and other commonly used statins.The prevalence of concomitant niacin-ER therapy in the statin-associated AERs was also calculated.
Outcomes: The amount of serious AERs associated with the combination lovastatin/niacin-ER was similar to that of lovastatin or niacin-ER alone, and significantly less than that of atorvastatin or simvastatin used alone. The rates of liver and rhabdomyolysis AERs associated with lovastatin/niacin-ER were similar to those of the other statins or niacin-ER uses alone and lower than those associated with simvastatin alone. The incidence of niacin-ER use in statin-associated AERs was less than 1%. The findings indicate that statins can safely be used in combination as indicated in the national guidelines